In this blog, Emily Klein reflects on the importance of Rare Disease Day in bringing visibility to those affected by a rare condition and serving as a focal point for advocacy in this space.
PrecisionLife and Ovation announce results of first phase to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like peptide-1 receptor agonist (GLP-1).
Located within the Glasgow Riverside Innovation District (GRID), the highly anticipated Health Innovation Hub (HiH) has secured Panthera as a new tenant ahead of its official opening next month.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced a £4.8 million (c. $6.5 million) extension to its Series C financing, in addition to the £14 million secured in March 2025, bringing the total in the round to £18.8 million (c. $25.4 million).
A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
22,000 sq ft of space in Wilton Centre’s Technical Development Area (TDA) has been leased to growing companies breathing new life into used metals and accelerating Teesside’s net zero ambitions.
In this blog, Katherine Powers, Life Sciences Senior Analyst at RSM US, and Max Stanyard, Life Sciences Senior Analyst at RSM UK, highlight the investment uncertainty in the UK-US life sciences ecosystem.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
The BIA has submitted its response to the HM Treasury's Business Rates and Investment: Call for Evidence, which sought to understand the impact of business rates on investment.
In this blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
Cancer Research Horizons adds the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.
